Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-gluco-pyranoside (MCNU) in dogs

  • 20 Accesses

  • 2 Citations

Summary

Ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU), a water soluble nitrosourea with log P-0.71, may be efficacious in the treatment of subarachnoid dissemination of malignant glioma. We used 2 dogs to study the neurotoxicity and pharmacokinetics of MCNU. MCNU (1 mg), dissolved in 10 ml of artificial CSF, was administered via the right lateral ventricle during a period of 18 to 42 min and the CSF was drained by lumbar puncture. The perfusion was repeated once a week for 10 consecutive weeks. No neurological and systemic symptoms were noted after perfusion. Histological examination of the brain and spinal cord showed local denudation of the ependyma and local subependymal spongy degeneration and gliosis in the lateral ventricle into which MCNU was administered in one dog and local denudation of the ependyma in the other. When administration was over a period of 21 to 38 min, the MCNU concentration in the lumbar CSF peaked at 11.11 to 50.67 Μg/ml, in 28 to 78 min. The area under the drug concentration-time curve (AUC) was 1152 Μg×min/ml on average, significantly larger than that of ACNU. The elimination phase followed linear kinetics and the half-time was 41.1 min on average, significantly longer than that of ACNU. These findings suggest that ventriculolumbar perfusion of MCNU may be effective in the treatment of subarachnoid dissemination of malignant glioma notwithstanding some local histological changes.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Edwards MS, Levin VA, Seager ML, Wilson CB: Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma. Child's Brain 8: 444–451, 1981

  2. 2.

    Shapiro WR, Posner JB, Ushio Y, Chernik NL, Young DF: Treatment of meningeal neoplasms. Cancer Treat Rep 61: 733–743, 1977

  3. 3.

    Fulton DS, Levin VA, Gutin PH, Edwards MSB, Seager ML, Stewart J, Wilson CB: Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 8: 285–291, 1982

  4. 4.

    Gutin PH, Weiss HD, Wiernik PH, Walker MD: Intrathecal N,N′,N″-triethylenethiophosphoamide[thio-TEPA (NCS6396)] in the treatment of malignant meningeal disease. Phase 1–2 study. Cancer (Phila.) 38: 1471–1475, 1976

  5. 5.

    Gutin PH, Levi JA, Wiernik PH, Walker MD: Treatment of malignant meningeal disease with intrathecal thio-TEPA: a phase 1 study. Cancer Treat Rep 61: 885–887, 1977

  6. 6.

    Uemura S: Experimental and clinical study of the treatment of malignant glioma. J Kumamoto Med Soc 59: 16–63, 1985

  7. 7.

    Ushio Y, Mogami H: Chemotherapy of malignant brain tumors. Jpn J Cancer Chemother 14: 3227–3233, 1987

  8. 8.

    Kochi M, Kuratsu J, Mihara Y, Inoue N, Takaki S, Sueyoshi N, Soyama N, Uemura S, Ushio Y: Intrathecal perfusion of ACNU. Neurotoxicity and intrathecal pharmacokinetics in dogs. Neurol Surg 17: 741–746, 1989

  9. 9.

    Kochi M, Kuratsu J, Mihara Y, Takaki S, Inoue N, Sueyoshi N, Uemura S, Ushio Y: Neurotoxicity and pharmacokinetics of intrathecal perfusion of ACNU in dogs. Cancer Res 50: 3119–3123, 1990

  10. 10.

    Kochi M, Kuratsu J, Mihara Y, Takaki S, Seto H, Uemura S, Ushio Y: Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidmyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride. Neurosurgery 33: 817–823, 1993

  11. 11.

    Ohashi K: Route of drug administration and pharmacokinetics. In: Nakano S (ed) Handbook of clinical pharmacology and therapeutics. Joho Kaihatsu Kenkyujo, Tokyo, 1987, Vol 3, pp 37–47

  12. 12.

    Blasberg RG: Pharmacodynamics and the blood-brain barrier. Natl Cancer Inst Monogr 46: 19–27, 1977

  13. 13.

    Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M: Cell killing action of cell cycle phase-non-specific antitumor agents is depend on concentration-time product. Cancer Chemother Pharmacol 21: 185–190, 1988

  14. 14.

    Yamashima T, Yamashita J, Shoin K: Neurotoxicity of local administration of two nitrosoureas in malignant gliomas. Neurosurgery 26: 794–800, 1990

Download references

Author information

Correspondence to Masato Kochi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kochi, M., Takaki, S., Kuratsu, J.-. et al. Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-gluco-pyranoside (MCNU) in dogs. J Neuro-Oncol 19, 239–244 (1994). https://doi.org/10.1007/BF01053277

Download citation

Key words

  • meningeal gliomatosis
  • methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-gluco-pyranoside
  • ventriculolumbar perfusion
  • toxicity
  • pharmacokinetics